Recently Introduced Products

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Indication</th>
<th>Potential Impact</th>
<th>Expected Avg. Annual Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yaz Plus</td>
<td>a) For conception control b) For treatment of moderate acne in women 14 years of age and older c) For improvement in folic acid status in women who choose to use oral contraception</td>
<td>$</td>
<td>$150.00</td>
</tr>
</tbody>
</table>

$: Est. drug plan expenditure increase of <1%* $$: Est. drug plan expenditure increase of 1-5%* $$$: Est. drug plan expenditure increase of >5%*

**Stribild® – Once daily, single tablet regimen for the treatment of HIV**

Stribild® is an AntiRetroviral Therapy (ART) approved for the treatment of HIV-1 infection in adults 18 years of age and older who have not received prior therapy. Stribild® is a 4-drug fixed dose combination tablet and is the first single tablet regimen that includes a drug in the class of Integrase Strand-Transfer Inhibitor (INSTI). The only other currently available INSTI is administered twice daily as part of a multi-pill regimen.

In clinical studies, Stribild® has demonstrated rapid and sustained viral suppression, low rates of resistance, along with a favourable tolerability and safety profile. Stribild® is priced at $45.52 per tablet which translates to an annual cost of approximately $16,615.

There is currently no cure for HIV. HIV infection continues to be a serious medical problem in Canada. The number of people living with HIV (including AIDS) increased by 11.4% from an estimated 64,000 in 2008 to 71,300 in 2011.1 The number of people newly infected with HIV in Canada in 2011 was estimated to be between 2,250 and 4,100.1

ART aims to reduce viral replication, improve survival and quality of life. Once-daily, single tablet dosing regimens are preferred as they simplify treatment and improve patient compliance.2 Patients taking their HIV medication, as directed, at least 95% of the time strongly correlates with HIV viral suppression, reduced rates of resistance, an increase in survival, and improved quality of life.3

To ensure that this medication is being used for the appropriate patient, and to ensure coordination with provincial public programs, Stribild® will be placed under Special Authorization for ClaimSecure groups that subscribe to the Managed Formulary, Specialty Drug, and Stop Loss Programs. For Open Drug Formularies, Stribild® will be fully covered.

If you require additional information about Stribild®, please contact the Clinical Services Department, at (905) 949-3031 or 1-888-479-7587 ext. 3031.

**Recommendation: Special Authorization**

ClaimSecure reserves the right to amend in part or in its entirety stated special authorization clinical guidelines

References:

* Based on the Financial Impact Analysis per 100,000 lives covered © 2013 ClaimSecure Inc.